Elderly individuals with mild cognitive impairment (MCI) may have incipient Alzheimer's disease (AD) and are the most likely targets for therapies directed at disease modification or slowing progression to the
endpoint of overt dementia. Identification of those individuals who will eventually develop AD is assuming urgent importance in many centers.
With the potential advent of disease-modifying drugs, biomarkers with good reliability, sensitivity, and specificity are needed. One promising biomarker for patients with incipient AD is hippocampal atrophy
assessed by magnetic resonance imaging (MRI).
No comments:
Post a Comment